CytoDyn Updates

https://www.cytodyn.com/newsroom/press-releases/detail/590/cytodyn-receives-positive-response-from-fda-in-regard-to

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

https://www.youtube.com/watch?v=tSnmdAy0yig&t=4s

CytoDyn updates on Brazil and US COVID-19 trial progress, files expanded use for HIV MDR patients CytoDyn Inc. CEO Nader Pourhassan tells Proactive its contract research organization in Brazil has met with the Brazilian Health Regulatory Agency and receiv...